The BluGlass Board and Management are pleased to provide the following update and Appendix 4C Quarterly Report for the three months ended 30 September 2026 (Q1 FY27).
Highlights
- Received a A$1.4 million (US$1.0 million) Phase II contract from U.S. photonics company Uviquity
- Entered an approximately A$286,000 (US$200,000) early-stage collaboration with a global photonics leader to assess a novel GaN-based device for scientific and medical applications
- Secured a A$8.0 million R&D financing facility with Rockford, replacing the existing A$2.27 million Radium facility and providing approximately A$5.4 million of additional funding liquidity after refinancing
- Subsequent to quarter-end, received the A$6.1 million FY26 R&D Tax Incentive refund in October, with A$2.75 million applied to the scheduled Rockford loan repayment
- Appointed major shareholder and global capital markets investor Yam Rubenstein as a Non-Executive Director
- Presented the Company’s GaN laser strategy to U.S. investors at the iAccess Alpha Virtual Best Ideas Fall Investment Conference
- Continued advancing BluGlass’s project-to-product strategy through customer-funded development programs targeting future product supply opportunities.
- Appointed CEO and Executive Director Jim Haden as Managing Director in July, aligning his title with his
existing responsibilities
The full Quarterly Report and Appendix 4C is available to download here: Bluglass September Quarter Report 2026
